Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  38.00 9.27% 448.00 440.00 448.00 450.00 410.00 410.00 131,639 16:35:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -20.5 -26.2 - 350

Silence Therapeutics Share Discussion Threads

Showing 50226 to 50249 of 50950 messages
Chat Pages: Latest  2014  2013  2012  2011  2010  2009  2008  2007  2006  2005  2004  2003  Older
DateSubjectAuthorDiscuss
22/9/2017
13:21
So Aviva sold down on Wednesday but ING and more interestingly Richard Griffiths increased their holdings. Reassuring to see RG increasing as he has held for long time, and especially reassuring that the increase is all to "Richard Griffiths & Family" rather than one of his subsidiary companies. If he still sees value adding at these levels, that is good enough for me.
callumross
22/9/2017
08:42
callumross - I don't think the £8.56m is materially inaccurate, just a bit confusing. They are quoting the book value at 30th June, where "available for sale financial assets" were in the accounts at £8.555m. However, I do think the "up over 200%" is inaccurate. Silence purchased the stake at an average price of $1.65, so at a current price of about $3.50, the increase is $1.85, which is an increase of 112%, so the stake in $ terms is up over 100% since purchase, not over 200%. "That capitalises the business still at just £133 million with the valuation being backed by net cash of £29.8 million as at 30th June along with shares in US listed peer Arrowhead Pharmaceuticals (ARWR) valued at £8.56 million and which are up over 200% since Silence’s purchase."
1gw
22/9/2017
08:26
There is a material inaccuracy in that Align Research report Richie. They state the value of the Arrowhead stake as £8.56m. In fact at last nights close of $3.50 it is worth $24m or around £18m.
callumross
22/9/2017
06:54
Interesting that Align Research have put a link to their Silence update out this morning in an official RNS, entitled "Align Research updates"
1gw
22/9/2017
06:19
Note sounds very positive and is confident silence will be bought out very soon at a substantial premium.
doc robinson
22/9/2017
06:07
http://www.alignresearch.co.uk/silence-therapeutics/positive-rnai-results-silences-critics/
richie666
21/9/2017
09:43
Well this is all very nice. I thought the muted shareprice reaction to the alny news yesterday was rather strange - and but for what presumably was a very large seller feeding the buying interest I imagine we would have had a much stronger move yesterday. It will be good to see any holdings notices that come out of yesterday's volume.
1gw
21/9/2017
05:51
The recent director buys around 150p clearly aren't intended to make a 10%-20% gain. Likewise the last financing round at >200p. Everyone knows what the end game is here and I am expecting a nice steady rise up to 250-300p region ahead of the November capital markets day. Should be fun
rogen83
20/9/2017
18:46
ALNY or ARWR in would be interesting
djnzloop
20/9/2017
15:19
Wouldn't be surprised if that's Woodford out
djnzloop
20/9/2017
13:30
I've just bought some more at closer to 180 but thought I'd try to ride the "year of rnai" a bit further, having seen alny up 30% or so in the pre-market.
1gw
20/9/2017
13:13
It does seem that way. Bought a few at 170 but took awhile to execute so suspect is one seller via one broker and hence the delays? Edit: And there it is the rump 2.8m sold and off the share price goes
waterloo01
20/9/2017
13:06
I know the trade listings aren't always reliable, but given the volume going through at 170p and the spread it looks to me like there is a big supply available at 170p. i.e. an existing holder happy to sell the news and take profit at that price after the recent scare.
1gw
20/9/2017
13:00
What's the chances that any big cash influx to ALYN will lead to the suggested take out of SLN?
waterloo01
20/9/2017
12:48
A long wait of over 10 years....but great news.
benson384
20/9/2017
12:43
I think the most important aspect here, aside from any IP and licensing fees attributable to SLN is that this will be the first RNAi candidate to reach the stage of a commercial drug. This will give a huge lift to the valuations of the whole sector. Been waiting years for this.
callumross
20/9/2017
12:11
who is buying all this stock at £1.70 , they obviously want it higher, on that basis i purchased a few to trade.
partner
20/9/2017
11:39
Huge volume of automatic trades going through.
callumross
20/9/2017
11:20
Probably be announcement from SLN later re this, given the IP case in the High Court. Makes you wonder if ALNY managed the newsflow earlier this month to get the disappointing news out first leaving the Patisiran news to be announced untarnished.
callumross
20/9/2017
11:10
ALNY announces positive Patisiran results! “We are very proud to report the first ever positive Phase 3 results for an RNAi therapeutic, marking the potential arrival of an entirely new class of medicines. This moment is the culmination of a 15-year journey of tireless work by countless contributors who have overcome enormous scientific and business challenges to make RNAi therapeutics a reality,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “This is an incredibly exciting milestone for Alnylam and RNAi, and most importantly for patients and their treating physicians and families. We extend our deepest gratitude to all the patients, investigators and study staff who participated in the APOLLO study – they made this important scientific progress possible.” ased on these positive results, Alnylam expects to file its first New Drug Application in late 2017 and first Marketing Authorisation Application shortly thereafter. Sanofi Genzyme is currently preparing for regulatory filings for patisiran in Japan, Brazil and other countries, to begin in the first half of 2018. Pending regulatory approvals, Alnylam will commercialize patisiran in the U.S., Canada and Western Europe, with Sanofi Genzyme commercializing the product in the rest of the world. “This is a significant milestone that supports our belief that RNAi therapeutics have the potential to become an innovative new class of medicines for patients with rare genetic diseases,” said Elias Zerhouni, M.D., President, Global R&D, Sanofi
callumross
18/9/2017
14:00
"Down to 125-130p on charts?" LOL!
callumross
18/9/2017
07:35
Down to 125-130p on charts?
tsmith2
15/9/2017
14:12
But whether that's punters buying the dip or professionals taking a considered view of what was released yesterday I have no means of telling. So I remain out for now. Very grateful to Ali for highlighting it as an opportunity with the Silence release on their own acquisition but think I need it to fall back a lot closer to $2 before going back in.
1gw
15/9/2017
14:09
Yes - up big on huge volume.
1gw
Chat Pages: Latest  2014  2013  2012  2011  2010  2009  2008  2007  2006  2005  2004  2003  Older
Your Recent History
LSE
SLN
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191121 02:58:58